Phillip Frost's Companies & Ventures

Phillip Frost's operating career has been built around three pharmaceutical platforms — each larger than the last, each a continuation of the same approach.

Key Pharmaceuticals, co-founded in 1972, was the proving ground. Frost and his partners commercialized the Nicoderm transdermal nicotine patch, a genuine product breakthrough that paired a clear medical need (smoking cessation) with novel drug-delivery technology. In 1986 Schering-Plough acquired Key for approximately $835 million, validating Frost as a real operator and giving him capital for the next chapter.

IVAX Corporation was that next chapter. Beginning in 1987, Frost converted IVAX from a small specialty-pharma name into one of the world's largest generic-drug companies through a long campaign of acquisitions and integrations. Generics is a brutally competitive business — the moat comes from scale, regulatory expertise, and operational discipline. By 2006, IVAX was large enough that Teva Pharmaceutical Industries acquired it for approximately $7.4 billion. The deal made Frost a billionaire and confirmed his pattern: build, integrate, hold for the long arc, sell to a strategic.

OPKO Health, his current and longest-running platform, has been his project since 2007. OPKO is a diversified diagnostics and pharmaceutical company built through both internal development and acquisitions, including PROLOR Biotech and Bio-Reference Laboratories. The 4Kscore prostate cancer test is one of OPKO's signature diagnostic products. During the pandemic, OPKO and BioReference were among the largest U.S. processors of COVID-19 PCR tests.

What makes OPKO unusual is the size and consistency of Frost's personal stake. He is by a wide margin the largest insider holder, and he has been filing SEC Form 4 insider purchases on OPKO with extraordinary regularity for many years. There is no other public-company CEO with quite his record of buying his own stock.